Across TCGA pan-cancer cohorts, YRDC Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated YRDC data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher YRDC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YRDC expression acts as an unfavorable survival marker.

BLCA, CESC, and SARC are the cancer types where YRDC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
CESC	OS	Median	All	0.102	0.588	.003	24	view →
SARC	DFS	Median	All	0.130	0.632	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: YRDC tumor-vs-normal RNA expression · all YRDC data types